Literature DB >> 15470043

Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling.

Hidekazu Shirota1, Mayda Gursel, Dennis M Klinman.   

Abstract

Repetitive TTAGGG motifs present at high frequency in mammalian telomeres can suppress Th1-mediated immune responses. Synthetic oligonucleotides (ODN) containing TTAGGG motifs mimic this activity and have proven effective in the prevention/treatment of certain Th1-dependent autoimmune diseases. This work explores the mechanism by which suppressive ODN block the induction of Th1 immunity. Findings indicate that these ODN inhibit IFN-gamma-induced STAT1 phosphorylation and IL-12-induced STAT3 and STAT4 phosphorylation. As a result, T-bet expression is reduced as is the maturation of naive CD4+ cells into Th1 effectors. These changes indirectly support the generation of Th2-dominated immune responses. Suppressive ODN may thus represent a novel approach to influence the Th1:Th2 balance in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470043     DOI: 10.4049/jimmunol.173.8.5002

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.

Authors:  Christian Bode; Takeshi Kinjo; W Gregory Alvord; Dennis M Klinman
Journal:  Carcinogenesis       Date:  2014-01-08       Impact factor: 4.944

3.  Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation.

Authors:  Christian Bode; Jing Wang; Dennis M Klinman
Journal:  Int Immunopharmacol       Date:  2014-10-12       Impact factor: 4.932

4.  Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.

Authors:  Chunsong Yu; Myunggi An; Evan Jones; Haipeng Liu
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

5.  Suppressive oligonucleotides inhibit inflammation in a murine model of mechanical ventilator induced lung injury.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

6.  Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes.

Authors:  Zhuo Wang; Zhong Deng; Nadia Dahmane; Kevin Tsai; Pu Wang; Dewight R Williams; Andrew V Kossenkov; Louise C Showe; Rugang Zhang; Qihong Huang; José R Conejo-Garcia; Paul M Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 7.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 8.  STAT4: genetics, mechanisms, and implications for autoimmunity.

Authors:  Benjamin D Korman; Daniel L Kastner; Peter K Gregersen; Elaine F Remmers
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

9.  Topical antisense-oligonucleotides targeting IFN-gamma mRNA improve incidence and severity of herpetic stromal keratitis by cytokine specific and sequence unspecific effects.

Authors:  Susanne Wasmuth; Dirk Bauer; Klaus-Peter Steuhl; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-21       Impact factor: 3.117

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.